TrialLancet (London, England)2009

Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.

Paul M Ridker et al.PubMed ↗Publisher ↗

Rosuvastatin 20 mglooks good hereFewer vascular events.Weak evidence: one subgroup.

What the trial testedrandomised · 2009

One subgroup

May have reduced vascular events in participants who achieved LDL cholesterol less than 1.8 mmol/L

−55%−66% to −40%

rosuvastatin 20 mg vs placebo, in participants who achieved LDL cholesterol less than 1.8 mmol/L

Bigger than 8 in 10 on the map

As reported

HR 0.45, 95% CI 0.34–0.60

One subgroup

May have reduced vascular events in participants who achieved hsCRP less than 2 mg/L

−62%−74% to −44%

rosuvastatin 20 mg vs placebo, in participants who achieved hsCRP less than 2 mg/L

Bigger than 9 in 10 on the map

As reported

HR 0.38, 95% CI 0.26–0.56

One subgroup

May have reduced vascular events in participants who achieved both LDL cholesterol less than 1.8 mmol/L and hsCRP less than 2 mg/L

−65%−77% to −46%

rosuvastatin 20 mg vs placebo, in participants who achieved both LDL cholesterol less than 1.8 mmol/L and hsCRP less than 2 mg/L

Bigger than 9 in 10 on the map

As reported

HR 0.35, 95% CI 0.23–0.54

One subgroup

May have reduced vascular events in participants who achieved one or neither target (LDL cholesterol <1.8 mmol/L and/or hsCRP <2 mg/L)

−33%−48% to −13%

rosuvastatin 20 mg vs placebo, in participants who achieved one or neither target (LDL cholesterol <1.8 mmol/L and/or hsCRP <2 mg/L)

Bigger than 7 in 10 on the map

As reported

HR 0.67, 95% CI 0.52–0.87

+1 more in the walkthrough ↓

Who was studied, and how

300people in the Role of Innate and Adaptive Immunity After Acute Myocardial Infarction BATTLE-AMI Study trial, from 2015

of them with cardiovascular disease, in this paper

Among participants who achieved LDL cholesterol less than 1.8 mmol/L, the trial randomly assignedassigned by chance

rosuvastatin 20 mg

placebo

May have reduced vascular events−55%

randomised · one subgroup

Among participants who achieved hsCRP less than 2 mg/L, the trial randomly assignedassigned by chance

rosuvastatin 20 mg

placebo

May have reduced vascular events−62%

randomised · one subgroup

the abstract, start to end

… per 100 person-years; hazard ratio [HR] 0.45, 95% CI 0.34-0.60, p<0.0001), and those achieving hsCRP less than 2 mg/L a 62% reduction (event rate 0.42 per 100 person-years; HR 0.38, 95% CI 0.26-0.56, p<0.0001).

… 0.38 per 100 person-years; adjusted HR 0.35, 95% CI 0.23-0.54), versus a 33% reduction in those who achieved one or neither target (event rate 0.74 per 100 person-years; HR 0.67, 95% CI 0.52-0.87) (p across …

… rate 0.24 per 100 person-years; HR 0.21, 95% CI 0.09-0.52).

← favours treatmentfavours comparator →

could be chance

Vascular eventsrosuvastatin 20 mg vs placebo, in participants who achieved LDL cholesterol less than 1.8 mmol/L

HR 0.450.34–0.60

Vascular eventsrosuvastatin 20 mg vs placebo, in participants who achieved hsCRP less than 2 mg/L

HR 0.380.26–0.56

Vascular eventsrosuvastatin 20 mg vs placebo, in participants who achieved both LDL cholesterol less than 1.8 mmol/L and hsCRP less than 2 mg/L

HR 0.350.23–0.54

Vascular eventsrosuvastatin 20 mg vs placebo, in participants who achieved one or neither target (LDL cholesterol <1.8 mmol/L and/or hsCRP <2 mg/L)

HR 0.670.52–0.87

Vascular eventsrosuvastatin 20 mg vs placebo, in participants who achieved LDL cholesterol less than 1.8 mmol/L and hsCRP less than 1 mg/L

HR 0.210.09–0.52

StatinsLipids

Statins × lipidshelps?mixed

unlikelylikely

0.500.50 without it

← favours treatmentfavours comparator →

this papermore certainless certain

1 / 6

364 papers cite itlatest 60 shown

2009

…

2014

2015

2016

2017

2018

2019

2020

2021

2022

2024

2025

2026

this paperpooled ittrialcites it

3 trials

NCT02428374phase 4300 enrolled2015 NCT00239681phase 317,802 enrolled2003 NCT03516903phase 2/phase 335 enrolled2018

Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.

What the trial testedrandomised · 2009

May have reduced vascular events in participants who achieved LDL cholesterol less than 1.8 mmol/L

May have reduced vascular events in participants who achieved hsCRP less than 2 mg/L

May have reduced vascular events in participants who achieved both LDL cholesterol less than 1.8 mmol/L and hsCRP less than 2 mg/L

May have reduced vascular events in participants who achieved one or neither target (LDL cholesterol <1.8 mmol/L and/or hsCRP <2 mg/L)

Who was studied, and how

Five numbers in the abstract

Where each one falls

Where it lands on the map

What it changes

Among 7 other studies

364 papers cite itlatest 60 shown

3 trials